SNP318

Phase 1Small molecule

SSciNeuro

SNP318 is one of 9 small molecule programs targeting Neurodegenerative Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neurodegenerative DiseaseActive, not recruiting

Neurodegenerative DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Neurodegenerative Disease

#DrugCompanyPhaseTrials

Nuplazid

AACADIA Pharmaceuticals Inc.

Approved

3 2

Robitussin

Aricept

1 4

Namenda

AbbVie

Preclinical

1 5

THK-5351

JJae Seung Kim

Phase 2

1 6

Intropin

Pfizer

Preclinical

—7

MC225

UUniversity Medical Center Groningen

Phase 2

1 8

Citicoline

UUniversity of Texas Southwestern Medical Center

SNP318

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Efficacy

NCT07199777

Clinical

Trials by Indication[1]

Efficacy1 trial

A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients

Not yet recruiting·SSciNeuro·Phase 2·NCT07199777·60 enrolled

Neurodegenerative Disease1 trial

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

Completed·SSciNeuro·Phase 1·NCT05792163·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SNP318. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SNP318 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SNP318. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SciNeuro company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSciNeuro

SNP318

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Efficacy1 trial

Neurodegenerative Disease1 trial

References

Drug Info

Quick Facts

Related News